Medication abortion care is a safe, effective, non-invasive option for ending an early pregnancy. Despite its 20-year safety record, people still face barriers to obtaining it, even during the pandemic.

I urge the administration to take immediate action to lift outdated restrictions on medication abortion care including:

● Lifting the FDA’s in-person dispensing requirement for mifepristone for the duration of the public health emergency; and

● Directing the FDA to review the Risk Evaluation and Mitigation Strategy (REMS) for mifepristone to determine whether a REMS remains necessary, or whether the goals and elements should be modified or removed from the approved strategy to best reflect scientific evidence and real world use.